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Original Paper 
Cancer that is arising from uncontrolled cell 
proliferation is a debilitating disease that has 
afflicted a noticeable proportion of the entire 
population of the world in all generations and led to 
killing of millions of people in each year (1-2). 
Surgery, radiation and chemotherapy are traditional 
approaches for cancer treatment; however, these 
methods are accompanied with many problems and 
side effects (3).  For example,although 
chemotherapeutic agents selectively kills cells which  
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Different generations of the immunotoxins could be targeting cancerous 
cells by interactions between ligand and cell surface specific antigens. 
Therefore, identification and characterization of these types of ligands and 
corresponding antigens, which are constantly growing, would be a milestone 
step to design a novel generation of immunotoxins. Bearing in mind, a 
profile of cell surface specific antigens was collected, and then the 
expressions of them were measured via in silico program on several normal 
and cancerous tissues. Corresponding ligands of the selected antigens were 
then investigated by String, and validated through docking process. On the 
other hand, structural and functional characteristics as well as post-
translational modifications of the ligands were examined. Finally, amino 
acids of ligands that are involved in interaction to antigens were determined. 
The results of this study led to introducing several antigens including Gp75, 
MAGEA3, APCs, PSA, and MSLN with high expression on the surface of 
some cancerous cells. Moreover, this investigation revealed HLA-A, 
ALDH3A2, MLANA, AR, CALB2, SILV, CALU, and GAGE1 as ligands 
with high affinity to one or more selected antigens. Meanwhile, ligand 
miniaturization led to design a new generation of ligands with 30 amino acid 
in length and limited in post-translational modification.Taken together, these 
results introduced a series of cell surface specific antigens which can use for 
cancer diagnosis, and provide a numerous of candidate ligands to develop a 
new generation of immunotoxins for targeting breast, prostate, ovary and 
melanoma cancer cells. 
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are more rapidly proliferating, however numerous of 
these drugs which are presently being used for 
cancer patients exhibit considerable adverse side 
effects on the human body, such as bleeding, hair 
loss, diarrhea, and immunosuppression (4). On the 
other hand, development of resistance to 
chemotherapy is considered a major hindrance to 
treatment of various cancers, as a notable proportion 
of tumors relapses and develops resistance, 
eventually resulting in multidrug resistance 
following exposure to multiple anticancer drugs with 
prevalent structure and mechanisms of action (5, 6). 
So, ideally anticancer agents should act exclusively 
against tumor cells; without side effects on the 
human body (7). Accordingly, in the new era of 
'precision' cancer medicine, new drug development 
has shifted from cytotoxic chemotherapy to 
molecularly targeted agents. In this regard, a 
growing number of monoclonal antibodies and 
immunotoxins have been approved for the treatment 
of malignancies(8-10). Immunotoxins that are hybrid 
proteins from targeting and killing moieties 
components must remain intact while in the systemic 
circulation, but it must disassemble inside the target 
cell in order to release the toxin (10, 11). These 
therapeutic agents takes advantage of some special 
properties of cancer cells, especially cell-surface 
specifics antigens as targets to eliminate the cancer 
cells in that they are sparing on the normal cells 
(12). However, the clinical development of 
immunotoxins suffering by a variety of problems, 
including poor antigen specificity, low cytotoxicity, 
nonspecific toxicities, immunogenicity, and 
production difficulties, which some of them 
considered in this study based on in silico 
simulation.  
 
MATERIALS AND METHODS 
In order to profile comprehensive ligands with 
targeting capacity of the cancerous cell surface 
specific antigens, at the first step these antigens were 
gathered. Subsequently, while their expressions of 
detected antigens were determined by literature, 
confirming via protein atlas program.  
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On the other hand, the nucleotide sequences and 
corresponding proteins of the ligands and matching 
antigens were retrieved from NCBI, Uniprot, and 
EMBL. Moreover, 3D structure of the selected 
antigens were retrieved or prepared via PDB, SWISS
-MODEL and or by Modeller program. Furthermore, 
corresponding ligands of the selected antigens were 
then determined by data survey and using of the 
String program. The protein sequences of the 
selected ligands were then analyzed via PTM tools 
assay. Finally, the binding affinity of the ligands to 
antigens were performed using Hex and Cluspro 
programs and then visualized their interaction via 
Pymol software. Moreover, in silico expression as 
well as interaction assays were carried out in at least 
triplicate, and the generated data were expressed as 
mean standard deviation. One-way analysis of 
variance (ANOVA) was used to analyze the antigen 
expression on different tissues. ANOVA was done 
by a Tukey post hoc test. Statistical significance was 
considered at P < 0.05. All statistical analyses were 
carried out with SPSS 16.0 (SPSS Inc., Chicago, IL, 
USA). 
 
RESULT 
The results of ligands profiling led to disclosure a 
numerous of ligands with capacity to targeting 
cancerous cell surface specific antigens (Table 1). 
As showed in this table, some of these ligands could 
be targeting several antigens of various malignant 
tissues such as HLA-A with 4 targets in Breast, 
Ovarian, Prostate, Melanoma, Skin and Prostate 
cancers that are including MSLN, SILV, MAGE1 
and MAGE3 antigens.  
Subsequently in order to evaluate the quality of 
ligand interaction to corresponding antigens, binding 
affinity as well as situation of interaction were 
determined (Figure 1). As showed in this figure 
HLA-A with binding affinity domain to MSLN, 
SILV, MAGE1 and MAGE3 antigens showed 
several amino acid in each interaction which could 
be applied in ligand designing.  
Targets Ligand Targets Ligand Targets Ligand Targets Ligand 
HSP70 HSPBP1 CTGF FN1 APCs FCGR2A CTGF BMP7 
SILV MLANA CTGF VEGFA APCs CALU FOLH1 FLNA 
SILV HLA-A CTGF BMP4 KLK3 AR FOLH1 Arc40 
HSP70 TP53 HER2 EGF KLK3 SERPINA1 FOLH1 KLK3 
HSP70 PARK2 HER2 SHC1 KLK3 SERPINA5 EphB2 EFNB2 
HSP70 BAG3 MAGE1 HLA-A KLK3 A2M EphB2 EFNB1 
HSP70 STIP1 MAGE3 HLA-A MSLN MUC16 EphB2 RASA1 
HSP70 STUB1 HER2 GRB7 MSLN HLA-DR15 EphB2 SRC 
HSP70 HSP90AA1 HER2 SRC MSLN HLA-A EphB2 TIAM1 
HSP70 HSF1 HER2 HSP90AA1 MUC16 MSLN EphB2 ITSN1 
HSP70 BAG1 HER2 ERBB2IP MUC16 LGALS1 EphB2 EFNA5 
SSTR2A SST HER2 GRB2 FAP PLAUR EphB2 EFNB3 
SSTR2A SHANK1 HER2 ERBB3 FAP DPP4 CEA SELE 
SSTR2A SSTR3 HER2 EGFR HSP70 HIF1A CEA HNRNPM 
        HSP70 HIF1A HER2 UBC 
Table 1. Ligands with corresponding cancerous cell surface specific antigens 
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Following to assessments the circumstances of the 
interaction, energy of binding affinity of the ligands 
to corresponding antigens were investigated (Figure 
2). This analysis led to disclosure results that were 
contradictory and or in line of the scoring of the 
interaction in some cases. However, as showed in 
this figure among selected ligands MLANA with the 
lowest energy have more affinity to corresponding 
antigen, SILV, which propounded as a suitable 
candidate in immunotoxin designing. Meanwhile, 
ligands miniaturizations led to achieving a series of 
small ligands with 30 amino acid in length (data not 
shown) which ought to more analysis.  
Figure 1. Situation of interaction of HLA-A to corresponding antigens A) ASILV, B) MSLN, C) MAGE3 and D) 
MAGE1 as an example of assessments 
Figure 2. Assessment the binding affinity of the selective ligands to corresponding antigens based on interaction energy 
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Moreover, post-translation modifications (PTM) of 
the selected ligands were then assessment (Figure 3 
and Table 2). As showed in the figure and confirmed 
in the table 2, among these ligands MLANA have 
lowest sites for PTM that advocated candidacy of 
this ligand for immunotoxin designing. 
On the other hand, in silico expression assays of the 
corresponding antigens of the selected ligands were 
investigated. This analysis led to reveal significant 
results, so that the most of them which were reported 
previously as specific cancerous antigens showed 
expression at various tissues on the normal and 
malignant condition (Figure 4). As showed in this 
figure, MSLN as a tumor specific antigen for lung 
cancers (13) could be expressed in various normal 
and cancerous tissues at different level . 
 
Figure 3. Post-translation modification assays of MLANA. A) Glycosylation and 
B) Phosphorylation  potency sites  
Glycosylation 
sits 
Phosphorylation 
Sulfurization 
sits 
Ligand 
Name 
2 H 0 CALB2 
0 H 6 CALU 
0 H 1 ALDH3A2 
0 L 0 MLANA 
0 L 0 AR 
4 H 0 SILV 
0 L 0 GAGE1 
1 H 0 HLA-A 
Table 2. Post-translation modification assays of the selected ligands. (H: high 
modification, L: low modification)  
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Conclusion 
Taken together, the results of this research provide a profile of native and engineered ligands with capacity 
to target cancerous cell surface antigens with target therapy vision. 
Figure 4. Comparative assessment of in silico expression of the MSLN on different tissues of malignant cells. Error bars 
indicate standard deviation  
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